Larry Wittenberg is a senior partner in Goodwin’s Technology and Life Sciences groups. Mr. Wittenberg co-founded the firm’s Life Sciences practice and previously served as Co-Chair of that practice and as national Co-Chair of Goodwin's Technology Companies & Life Sciences group, and the firm’s Healthcare Technology and Services practice. He has more than 30 years’ experience representing life science and healthcare technology companies, ranging in size from start-ups to public companies, in corporate and intellectual property transactions and general corporate matters. This work has included numerous venture capital financings, public offerings, mergers and acquisitions, strategic alliances, collaborations, joint ventures, and license agreements. Mr. Wittenberg also represents venture capital groups on their investments in life sciences companies and investment banks in connection with public and private financings. He has structured and negotiated corporate partnering transactions with numerous global pharmaceutical companies.





Mr. Wittenberg’s practice focuses primarily on biotechnology, medtech and healthcare IT companies. His recent representations include:

  • Acetylon Pharmaceuticals, Inc. in its collaborative agreement with Celgene Corporation Action Pharma, in the $110 million sale to Abbott Laboratories
  • Abide Therapeutics, Inc., in its $430 million collaboration with Merck
  • Abide Therapeutics in its collaborative agreement with Celgene Corporation
  • Abide Therapeutics in its sale to Lundbeck
  • Akashi Therapeutics in its $100 million partnership with Gruenthal Group
  • Dragonfly Therapeutics in its collaborative agreements with Celgene Corporation, Merck, Abbvie, and BMS
  • Patient Ping in its $31 million Series B financing
  • QPID Health in its sale to eviCore healthcare
  • Vascular Biogenics in its US IPO and various follow-on public offerings
  • C4 Therapeutics in its launch from Dana-Farber Cancer Institute, $73 million Series A financing
  • C4 Therapeutics in its strategic collaborations with Roche, Calico Life Sciences and Biogen
  • Vividion Therapeutics in its $50 million Series A financing
  • Acetylon Pharmaceuticals in its spin-out of Regenacy Pharmaceuticals and sale to Celgene Corporation
  • Skyhawk Therapeutics in its strategic collaborations with Biogen, Merck, Celgene, Genentech and Takeda
  • Saniona A/S in establishing its US operations and its cross border crossover financing
  • C4 Therapeutics in its $130M crossover financing and $200M IPO
Professional Activities

Mr. Wittenberg serves on the board of directors of MassBio, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.

Professional Experience

Prior to joining Goodwin, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he co-founded and headed its Life Sciences Practice and co-chaired its Business Practice Group.


Mr. Wittenberg has been recognized by The Best Lawyers in America Best Lawyers for his work in Biotechnology, Life Sciences Practice and Corporate Law 2022-2023.

Mr. Wittenberg has been selected for inclusion in U.S. News-Best Lawyers.

In The News









JD, 1979
Harvard Law School
(cum laude)
BA, 1976
Cornell University
(magna cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique